TREATMENT OF HIDRADENITIS SUPPURATIVA
Hidradenitis suppurativa can be treated by administering a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α.
1 . A method of treating hidradenitis suppurativa in a human subject having lesions associated with hidradenitis suppurativa, the method comprising the step of administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of an anti-IL-1α antibody effective to treat a symptom of hidradenitis suppurativa in the subject.
2 . The method of claim 1 , wherein the anti-IL-1α antibody is a monoclonal antibody.
3 . The method of claim 2 , wherein the monoclonal antibody is an IgG1.
4 . The method of claim 3 , wherein the monoclonal antibody is MABp1.
5 . The method of claim 1 , wherein the subject's HiSCR score is improved after administration of the pharmaceutical composition
6 . The method of claim 1 , wherein the median size of the subject's hidradenitis suppurativa lesions is reduced after administration of the pharmaceutical composition.
7 . The method of claim 1 , wherein the subject's pain associated with the subject's hidradenitis suppurativa lesions is reduced after administration of the pharmaceutical composition.
8 . The method of claim 1 , wherein the subject's time to new hidradenitis suppurativa lesions is increased after administration of the pharmaceutical composition.
9 . The method of claim 1 , wherein the hidradenitis suppurativa in the human subject has failed to resolve after treatment with tumor necrosis factor alpha inhibitors.
10 . The method of claim 1 , further comprising the step of administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an anti- S. aureus antibody.
11 . The method of claim 10 , wherein the anti- S. aureus antibody comprises a Fab region paratope that specifically binds to S. aureus protein A (SpA) and an Fc region that does not specifically bind SpA.